The research-to-practice gap in mood disorders: A role for the U.S. Department of Veterans Affairs

Journal of Clinical Psychiatry

Volumn 68, Issue 4, 2007, Pages 502-504

  Kilbourne, Amy M ^a   Valenstein, Marcia ^a   Bauer, Mark S ^b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BROWN UNIVERSITY   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM;

BIPOLAR DISORDER; CLINICAL TRIAL; COMMUNITY CARE; COMORBIDITY; ELECTRONIC MEDICAL RECORD; FOLLOW UP; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH HAZARD; HEALTH MAINTENANCE ORGANIZATION; HEALTH SERVICE; HUMAN; INFORMATION PROCESSING; MAJOR DEPRESSION; MEDICAL PRACTICE; MEDICAL RESEARCH; MOOD DISORDER; NOTE; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; UNITED STATES; VETERAN; WORLD HEALTH ORGANIZATION;

EID: 34247514280     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0402     Document Type: Note

References (48)

1. Institute of Medicine. Assessing Medical Technologies. Washington, DC: National Academy Press; 1985
2. Committee on Quality Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001
3. Lieberman JA. Comparative effectiveness of antipsychotic drugs: a commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS I) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006;63:1069-1071
4. Rosenheck RA. Outcomes, costs, and policy caution: a commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS I). Arch Gen Psychiatry 2006;63:1074-1076
5. Wells K. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999;156:5-10
6. Bauer MS, Williford W, Dawson E, et al. Principles of effectiveness trials and their implementation in VA Cooperative Study #430, "Reducing the Efficacy-Effectiveness Gap in Bipolar Disorder." J Affect Disord 2001;67:61-78
7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
8. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
9. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-131
10. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243
11. Bauer MS. Bipolar (manic-depressive) disorder. In: Tasman A, Kay J, Lieberman J, eds. Psychiatry. 2nd ed. Philadelphia, Pa: Saunders; 2003: 1237-1270
12. Anderson G, Knickman JR. Changing the chronic care system to meet people's needs. Health Aff (Millwood) 2001;20:146-160
13. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-226
14. Kupfer DJ, Frank E. Comorbidity in depression. Acta Psychiatr Scand Suppl 2003;418:57-60
15. Bauer MS, Altshuler L, Evans DR, et al. Prevalence and distinct orrelates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord 2005;85:301-315
16. Simon NM, Otto MW, Weiss RD, et al. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from the first 1000 participants in STEP-BD. J Clin Psychopharmacol 2004;24:512-520
17. Fenn HH, Bauer MS, Altshuler L, et al. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J Affect Disord 2005;86:47-60
18. Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord 2004;6:368-373
19. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005;293:2528-2530
20. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric-outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005;162:1370-1372
21. Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry 2006;67:1412-1421
22. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006;188:313-320
23. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566
24. Lambert BL, Cunningham FE, Miller DR, et al. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 2006;164:672-681
25. Kilbourne AM, Schulberg HC, Post EP, et al. Translating evidence-based depression management services to community-based primary care practices. Milbank Q 2004;82:631-659
26. Roy-Byrne PP, Sherbourne CD, Craske MG, et al. Moving treatment research from clinical trials to the real world. Psychiatr Serv 2003;54:327-332
27. Prien R, Rush AJ. National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder. Biol Psychiatry 1996;40:215-220
28. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836-846
29. Geddes JR, Rendell JM, Goodwin GM. BALANCE: a large simple trial of maintenance treatment for bipolar disorder. World Psychiatry 2002;1:48-51
30. Glasgow RE, Lichtenstein E, Marcus AC. Why don't we see more translation of health promotion research to practice? rethinking the efficacy-to- effectiveness transition. Am J Public Health 2003;93:1261-1267
31. Blow FC, McCarthy JF, Valenstein M, et al. Care in the VHA for Veterans With Psychosis: FY2004. Sixth Annual Report on Veterans With Psychoses. Ann Arbor, Mich: VA National Serious Mental Illness Treatment Research and Evaluation Center; November 2004
32. Yano EM, Bastian LA, Frayne SM, et al. Toward a VA women's health research agenda: setting evidence-based priorities to improve the health and health care of women veterans. J Gen Intern Med 2006;21:S93-S101
33. VA Health Care Atlas, 2000. Available at: http://www1.va.gov/rorc/ products.cfm. Accessibility verified February 14, 2007
34. Craddock N, Owen MJ. The beginning of the end for the Kraepelinian dichotomy. Br J Psychiatry 2005;186:364-366
35. MacQueen GJ, Hajek T, Alda M. The phenotypes of bipolar disorder: relevance for genetic investigations. Mol Psychiatry 2005;10:811-826
36. Prien R, Caffey E, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Arch Gen Psychiatry 1972;26:146-153
37. Prien RF, Caffey EM, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973;28:337-341
38. Prien RF, Klett CJ, Caffey EM. Lithium carbonate and Imipramine in prevention of affective episodes. Arch Gen Psychiatry 1973;29:420-425
39. Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting. JAMA 2002;288:2836-2845
40. Bauer MS, McBride L, Williford WO, et al. Collaborative care for bipolar disorder, pt 2: impact on clinical outcome, function, and costs. Psychiatr Serv 2006;57:937-945
41. Bauer MS, McBride L, Williford WO, et al. Collaborative care for bipolar disorder, pt 1: intervention and implementation in a randomized effectiveness trial. Psychiatr Serv 2006;57:927-936
42. Simon GE, Ludman EJ, Bauer MS, et al. Long-term effectiveness and cost of a systematic care management program for bipolar disorder. Arch Gen Psychiatry 2006;63:500-508
43. National Institutes of Mental Health. Dissemination and implementation research in mental health program announcement. 2005. Available at: http://grants.nih.gov/grants/guide/pa-files/PAR-06-039.html. Accessibility verified February 14, 2007
44. Felker BL, Chaney E, Rubenstein LV, et al. Developing effective collaboration between primary care and mental health providers. Prim Care Companion J Clin Psychiatry 2006;8:12-16
45. Chinman M, Young AS, Hassell J, et al. Toward the implementation of mental health consumer provider services. J Behav Health Serv Res 2006;33:176-195
46. Fudala PJ, Vocci F, Montgomery A, et al. Levomethadyl acetate (LAAM) for the treatment of opioid dependence: a multisite, open-label study of LAAM safety and an evaluation of the product labeling and treatment regulations. J Maint Addict 1997;1:9-39
47. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949-958
48. Elkashef A, Fudala PJ, Gorgon L, et al. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. Drug Alcohol Depend 2006;85:191-197